# JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

> clinical trial · VERIFIED · 2026-07-15

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Heart, Lung, and Blood Institute (NHLBI) · Condition: Severe Aplastic Anemia

- Company: National Heart, Lung, and Blood Institute (NHLBI)
- Sector: Severe Aplastic Anemia
- Primary source: https://clinicaltrials.gov/study/NCT05998408

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.